Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
BHVNthis companyBiohaven Ltd.	$15.18	-1.65×	23.33×	0×	-1.75×	-103.9%	0.0%	0.0%	0.0%	-1418.8%	-218.4%	-50.2%	5.47×	-0.08×	0×	3.18×	0.0%	3	-15.51	2	C
CLDXCelldex Therapeutics, Inc.	$31.21	-6.96×	3.43×	1,204.09×	-6.97×	-99.2%	100.0%	-19160.0%	-17253.3%	-49.1%	-53.9%	-11.8%	0×	0.1×	0×	10.49×	0.0%	2	16.42	2	C
IMNMImmunome, Inc.	$19.48	-8.84×	2.96×	270.32×	-5.86×	-62.3%	57.4%	-3084.8%	-3060.0%	-33.5%	-33.5%	-10.7%	0.01×	3.1×	0×	14.69×	0.0%	2	31.88	2	C+
NTLAIntellia Therapeutics, Inc.	$11.84	-2.36×	1.45×	14.4×	-2.3×	-249.6%	76.5%	-651.7%	-609.9%	-61.5%	-57.7%	-36.4%	0.14×	0.16×	0×	5.08×	0.0%	4	2.17	2	C
SIONSionna Therapeutics, Inc.	$3.50	-21.88×	5.36×	0×	-21.36×	-67.1%	0.0%	0.0%	0.0%	-24.5%	-28.2%	-4.1%	0.03×	0.67×	0×	20.61×	0.0%	0	4.01	2	C
VERAVera Therapeutics, Inc.	$29.92	-10.87×	5.38×	0×	-10.2×	-86.6%	0.0%	0.0%	0.0%	-49.6%	-46.3%	-7.4%	0.13×	0.95×	-41.89×	13.64×	0.0%	1	6.48	1	C-
Peer median	—	-8.84×	3.43×	14.4×	-6.97×	-86.6%	57.4%	-651.7%	-609.9%	-49.1%	-46.3%	-10.7%	0.03×	0.67×	0×	13.64×	0.0%	2	6.48	2	—